var data={"title":"Imaging of lung cancer","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Imaging of lung cancer</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/contributors\" class=\"contributor contributor_credentials\">Paul Stark, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/contributors\" class=\"contributor contributor_credentials\">Nestor L Muller, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/contributors\" class=\"contributor contributor_credentials\">Geraldine Finlay, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/contributors\" class=\"contributor contributor_credentials\">Sadhna R Vora, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/contributors\" class=\"contributor contributor_credentials\">Susanna I Lee, MD, PhD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 15, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When a patient presents with suspected non-small cell lung cancer (NSCLC), multiple imaging tests are required. While NSCLC is the most common lung cancer, the same principles of imaging described in this topic also apply to patients with small cell lung cancer (SCLC) [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/1\" class=\"abstract_t\">1</a>]. </p><p>Imaging modalities used in the evaluation of patients with known or suspected NSCLC and representative images are reviewed here. Selection of imaging and invasive staging modalities are discussed separately. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;</a> and <a href=\"topic.htm?path=selection-of-modality-for-diagnosis-and-staging-of-patients-with-suspected-non-small-cell-lung-cancer\" class=\"medical medical_review\">&quot;Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer&quot;</a> and <a href=\"topic.htm?path=procedures-for-tissue-biopsy-in-patients-with-suspected-non-small-cell-lung-cancer\" class=\"medical medical_review\">&quot;Procedures for tissue biopsy in patients with suspected non-small cell lung cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3706647543\"><span class=\"h1\">GOALS OF IMAGING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with known or suspected lung cancer, imaging achieves the following goals:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Detects tumor characteristics</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Determines the radiologic disease stage </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Identifies lesions that warrant tissue sampling for diagnosis and staging </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Assists in planning surgical or radiation therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Restages disease extent after therapy</p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">TNM STAGING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The staging of NSCLC is based upon the tumor node metastasis (TNM) staging system, which coordinates tumor size (T), extent of regional lymph node involvement (N), and presence or absence of distant metastasis (M). The combination of T, N, and M grades determines the overall disease stage (stage I through IV).</p><p>The eighth edition of the TNM staging system (<a href=\"image.htm?imageKey=ONC%2F109805\" class=\"graphic graphic_table graphicRef109805 \">table 1</a> and <a href=\"image.htm?imageKey=ONC%2F109806\" class=\"graphic graphic_table graphicRef109806 \">table 2</a>) is in effect. TNM staging systems for lung cancer are described in detail separately. (See <a href=\"topic.htm?path=tumor-node-metastasis-tnm-staging-system-for-lung-cancer\" class=\"medical medical_review\">&quot;Tumor, Node, Metastasis (TNM) staging system for lung cancer&quot;</a>.) </p><p>The approach to staging is discussed separately. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;</a> and <a href=\"topic.htm?path=selection-of-modality-for-diagnosis-and-staging-of-patients-with-suspected-non-small-cell-lung-cancer\" class=\"medical medical_review\">&quot;Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer&quot;</a> and <a href=\"topic.htm?path=procedures-for-tissue-biopsy-in-patients-with-suspected-non-small-cell-lung-cancer\" class=\"medical medical_review\">&quot;Procedures for tissue biopsy in patients with suspected non-small cell lung cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">IMAGING MODALITIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>While many patients with new-onset respiratory symptoms are evaluated with chest radiography, those with signs or symptoms concerning for NSCLC proceed with computed tomography (CT) of the chest. Advanced imaging modalities including positron emission tomography (PET), and integrated <span class=\"nowrap\">PET/CT</span> are also useful [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/2\" class=\"abstract_t\">2</a>]. Less commonly used modalities include magnetic resonance imaging (MRI) and radionuclide bone scanning. Integrated <span class=\"nowrap\">PET/MRI</span> remains investigational. Technical aspects are reviewed here, while indications for these modalities are discussed elsewhere. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H108294217\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Radiographic staging'</a>.)</p><p>Importantly, imaging modalities are insufficient to definitively diagnose and stage lung cancer such that, with the exception of brain, tissue biopsy of the primary tumor <span class=\"nowrap\">and/or</span> metastases is necessary. (See <a href=\"topic.htm?path=selection-of-modality-for-diagnosis-and-staging-of-patients-with-suspected-non-small-cell-lung-cancer\" class=\"medical medical_review\">&quot;Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer&quot;</a> and <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H98206806\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Chest radiography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chest radiography alone is insufficient for diagnosis and staging of NSCLC. However, chest radiography is readily available, inexpensive, and provides information regarding the presence and extent of a possible malignancy, with a minimal effective radiation dose (<a href=\"image.htm?imageKey=PULM%2F111651\" class=\"graphic graphic_diagnosticimage graphicRef111651 \">image 1</a>). Thus, it is frequently the initial test performed to evaluate symptoms suggestive of lung cancer that prompt CT of the chest. </p><p>Many of the features identified on chest radiography that increase the suspicion for malignancy are similar but better defined on CT (eg, large size, growth, irregular border, eccentric calcification, part-solid attenuation, upper lobe location). Imaging features that help distinguish benign from malignant pulmonary nodules and the approach to patients with nodules are discussed separately. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H98205022\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Initial imaging'</a> and <a href=\"topic.htm?path=diagnostic-evaluation-of-the-incidental-pulmonary-nodule\" class=\"medical medical_review\">&quot;Diagnostic evaluation of the incidental pulmonary nodule&quot;</a> and <a href=\"topic.htm?path=computed-tomographic-and-positron-emission-tomographic-scanning-of-pulmonary-nodules\" class=\"medical medical_review\">&quot;Computed tomographic and positron emission tomographic scanning of pulmonary nodules&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3511855298\"><span class=\"h3\">Radiation dose</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The effective radiation dose associated with chest radiography is low and approximately 0.02 milliSievert (mSv) for a frontal chest radiograph and 0.06 mSv for a lateral chest radiograph [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/3,4\" class=\"abstract_t\">3,4</a>]. Noteworthy is that natural background radiation is approximately 3 mSv per year [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/5\" class=\"abstract_t\">5</a>]. Radiation dose for CT chest is discussed below. (See <a href=\"#H2853752449\" class=\"local\">'Radiation dose'</a> below.)</p><p>Digital tomosynthesis has been described but has primarily found applications in breast imaging rather than in lung cancer staging [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/6\" class=\"abstract_t\">6</a>]. (See <a href=\"topic.htm?path=breast-imaging-for-cancer-screening-mammography-and-ultrasonography\" class=\"medical medical_review\">&quot;Breast imaging for cancer screening: Mammography and ultrasonography&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Computed tomography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CT of the chest and upper abdomen (including adrenals) should be performed in all patients with suspected NSCLC to characterize the size of the tumor and any potential lymph node metastases (<a href=\"image.htm?imageKey=PULM%2F111656\" class=\"graphic graphic_diagnosticimage graphicRef111656 \">image 2</a> and <a href=\"image.htm?imageKey=PULM%2F111657\" class=\"graphic graphic_diagnosticimage graphicRef111657 \">image 3</a> and <a href=\"image.htm?imageKey=PULM%2F111652\" class=\"graphic graphic_diagnosticimage graphicRef111652 \">image 4</a> and <a href=\"image.htm?imageKey=PULM%2F111653\" class=\"graphic graphic_diagnosticimage graphicRef111653 \">image 5</a>). In addition, dedicated CT of abdomen or brain may identify potential extrathoracic metastatic disease. The identification and characterization of disease extent by CT facilitates the selection of modality and site for biopsy to diagnose <span class=\"nowrap\">and/or</span> stage patients with NSCLC. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H108294217\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Radiographic staging'</a> and <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H108294779\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'CT scan of the chest'</a> and <a href=\"topic.htm?path=selection-of-modality-for-diagnosis-and-staging-of-patients-with-suspected-non-small-cell-lung-cancer\" class=\"medical medical_review\">&quot;Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Technique</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A reconstructed slice thickness of 1 to 1.25 mm for lung imaging and 2 to 2.5 mm for mediastinal and chest wall imaging are typical of multislice CT for the chest, while a slice thickness of 10 mm is typical for CT of the brain. A properly performed CT scan of the chest should visualize all of the chest wall and all thoracic structures from the base of the neck to below the adrenal glands, which are a common site of metastatic spread. CT scans of the brain should visualize the head from the vertex through the base of the skull, including the brain, skull, eye sockets, and sinuses.</p><p>Intravenous contrast material should be used for CT scans of brain (although MRI is preferred) and, when indicated, for CT of the chest [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/7\" class=\"abstract_t\">7</a>]. Although with many newer CT scanners, intravenous contrast material is not always necessary when imaging the chest, it may help distinguish vascular structures from nonvascular (normal and abnormal) mediastinal structures, particularly when mediastinal invasion is suspected and atelectasis is present. It also facilitates assessment of potential vascular involvement of the superior vena cava, pulmonary veins, pulmonary arteries, systemic mediastinal arterial structures, and cardiac structures. With respect to CT scans of the brain, intravenous contrast material should be used to identify metastatic lesions that may otherwise remain undetected.</p><p>Thick-slab sliding maximum intensity projection imaging (MIP; eg, sliding MIP utilizing 8 mm slabs with 2 mm overlap) is also helpful in differentiating nodules from vascular structures seen in cross-section. Additional advantages of CT include densitometric analysis of nodules (facilitating the detection of fat, calcium, or enhancement after intravenous contrast material injection) and the ability to display images in axial, sagittal, coronal, or oblique planes with the help of near-isotropic multiplanar reformatting. Computer-aided diagnosis software can facilitate detection of nodules and suppress signal from vascular structures that could mimic pulmonary nodules.</p><p class=\"headingAnchor\" id=\"H2853752449\"><span class=\"h3\">Radiation dose</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The effective radiation dose for CT of the chest varies between 5 and 10 mSv, which is approximately 50 to 100 times more than that for chest frontal and lateral radiographs [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"#H3511855298\" class=\"local\">'Radiation dose'</a> above.)</p><p>All individuals are exposed to natural background radiation of approximately 3 mSv per year [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/5\" class=\"abstract_t\">5</a>]. Airline pilots and flight attendants receive an additional 3 to 5 mSv per year. Studies of atomic bomb survivors from Japan suggest that the risk of developing cancer increases when radiation exposure exceeds 50 mSv or 100 mSv. Whether the risk of cancer is increased with less radiation exposure is uncertain and controversial [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/8\" class=\"abstract_t\">8</a>]. To minimize radiation exposure, follow-up CT of the chest can be performed using low radiation protocols, which provide effective radiation doses of only 0.5 to 1.5 mSv [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/9,10\" class=\"abstract_t\">9,10</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Tumor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CT assessment of the following features is generally sufficient to assess local extent of the tumor (ie, T stage of the TNM classification):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tumor size</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence or absence of separate tumor nodule(s).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence or absence of atelectasis or obstructive pneumonia.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Possible invasion of adjacent structures.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Proximal extent of the tumor </p><p/><p>The following images demonstrate the value of CT for tumor characterization. Descriptions are made per the eighth edition (<a href=\"image.htm?imageKey=ONC%2F109805\" class=\"graphic graphic_table graphicRef109805 \">table 1</a> and <a href=\"image.htm?imageKey=ONC%2F109806\" class=\"graphic graphic_table graphicRef109806 \">table 2</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>T1a lesions are &le;1 cm in greatest diameter, while T1b lesions are &gt;1cm and &le;2 cm in greatest diameter, and T1c lesions are &gt;2 cm but &le;3 cm in greatest diameter. All T1 lesions are surrounded by lung or visceral pleura, without evidence of invasion proximal to a lobar bronchus. An additional separate T1a (minimally invasive adenocarcinoma) has been suggested (<a href=\"image.htm?imageKey=PULM%2F112827\" class=\"graphic graphic_diagnosticimage graphicRef112827 \">image 6</a>). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>T2a lesions are &gt;3 cm but &le;4 cm in diameter (<a href=\"image.htm?imageKey=PULM%2F57134\" class=\"graphic graphic_diagnosticimage graphicRef57134 \">image 7</a>), while T2b lesions are &gt;4 cm but &le;5 cm. T2 lesions also include tumors of any size that invade the visceral pleura, involves the main bronchus regardless of distance from the carina but not involving the carina (<a href=\"image.htm?imageKey=PULM%2F56988\" class=\"graphic graphic_diagnosticimage graphicRef56988 \">image 8</a> and <a href=\"image.htm?imageKey=PULM%2F111661\" class=\"graphic graphic_diagnosticimage graphicRef111661 \">image 9</a>), or are associated with atelectasis or obstructive pneumonia that extends to the hilum involving part or all of the lung.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>T3 lesions are &gt;5 cm and &le;7cm in greatest diameter (<a href=\"image.htm?imageKey=PULM%2F59036\" class=\"graphic graphic_diagnosticimage graphicRef59036 \">image 10</a>). Alternatively, they can be tumors of any size that directly invade the chest wall (<a href=\"image.htm?imageKey=PULM%2F73744\" class=\"graphic graphic_diagnosticimage graphicRef73744 \">image 11</a> and <a href=\"image.htm?imageKey=PULM%2F53784\" class=\"graphic graphic_diagnosticimage graphicRef53784 \">image 12</a>), phrenic nerve (<a href=\"image.htm?imageKey=PULM%2F71610\" class=\"graphic graphic_diagnosticimage graphicRef71610 \">image 13</a> and <a href=\"image.htm?imageKey=PULM%2F111655\" class=\"graphic graphic_diagnosticimage graphicRef111655 \">image 14</a>), parietal pleura, superior sulcus, and parietal pericardium, as well as tumors of any size that are associated with separate tumor nodule(s) in the same lobe.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>T4 lesions are tumors &gt;7 cm or tumors that are associated with separate tumor nodule(s) in a different ipsilateral lobe or have extensive invasion of the diaphragm, mediastinum, carina, heart, pericardium, great vessels (<a href=\"image.htm?imageKey=PULM%2F58664\" class=\"graphic graphic_diagnosticimage graphicRef58664 \">image 15</a>), trachea, recurrent laryngeal nerve, esophagus (<a href=\"image.htm?imageKey=PULM%2F64447\" class=\"graphic graphic_diagnosticimage graphicRef64447 \">image 16</a>), and vertebral body(ies) (<a href=\"image.htm?imageKey=PULM%2F105319\" class=\"graphic graphic_diagnosticimage graphicRef105319 \">image 17</a>).</p><p/><p>Additional imaging studies are usually unnecessary for tumor characterization and determining T stage. However, PET with 18-fluoro-2-deoxyglucose (FDG) may help distinguish tumor from peritumoral atelectasis, thus preventing overestimation of the tumor's size [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/2,11\" class=\"abstract_t\">2,11</a>] (see <a href=\"#H10\" class=\"local\">'Positron emission tomography'</a> below). MRI is the best modality for determining the presence and extent of invasion of the chest wall, spine, or brachial plexus, as well as detecting transdiaphragmatic growth of the tumor [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/12-14\" class=\"abstract_t\">12-14</a>] (see <a href=\"#H20\" class=\"local\">'Magnetic resonance imaging'</a> below). Transesophageal echocardiography may be useful for detecting mediastinal or vascular invasion in selected patients [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/15,16\" class=\"abstract_t\">15,16</a>]. (See <a href=\"topic.htm?path=transesophageal-echocardiography-indications-complications-and-normal-views\" class=\"medical medical_review\">&quot;Transesophageal echocardiography: Indications, complications, and normal views&quot;</a>.)</p><p>In addition, CT chest can also provide valuable information on any potential underlying lung disease that may affect procedural or prognosis risk (eg, severe bullous disease). (See <a href=\"topic.htm?path=evaluation-of-preoperative-pulmonary-risk\" class=\"medical medical_review\">&quot;Evaluation of preoperative pulmonary risk&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Lymph nodes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The value of CT for the detection of lymph node metastases in patients with known or suspected NSCLC depends upon the detection of lymph node enlargement (<a href=\"image.htm?imageKey=ONC%2F73945\" class=\"graphic graphic_figure graphicRef73945 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/17\" class=\"abstract_t\">17</a>]. However, CT staging assignment is imperfect such that metastatic disease can exist in normal size lymph nodes, and benign lymph nodes can be enlarged. Thus, biopsy in addition to CT scan is required for accurate staging. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H761452\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Tissue biopsy'</a>.)</p><p>Regarding the CT evaluation of lymph nodes, in general:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most normal mediastinal lymph nodes measure less than 10 mm in short axis [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/2,18\" class=\"abstract_t\">2,18</a>], although normal subcarinal lymph nodes can reach a diameter of 13 to 15 mm. Nodes exceeding these sizes are more likely to contain malignant disease in patients with lung cancer. Overall, lymph nodes less than 10 mm in short axis contain tumor cells in less than 13 percent of patients. Lymph nodes between 10 and 15 mm in short axis have a 50 percent probability of containing tumor cells and lymph nodes exceeding 15 mm in short axis have a probability of more than 67 percent for tumor involvement [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normal lymph nodes are rarely seen in the retrocrural region, para-aortic region, or pericardial fat. Lymph nodes exceeding 8 mm in these regions should be considered suspicious [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/2,19\" class=\"abstract_t\">2,19</a>].</p><p/><p>Mediastinal lymph nodes are graded on the basis of the absence or presence and location of lymph node enlargement. Descriptions in this section are per the eighth edition for the staging classification for lung cancer (<a href=\"image.htm?imageKey=ONC%2F109805\" class=\"graphic graphic_table graphicRef109805 \">table 1</a> and <a href=\"image.htm?imageKey=ONC%2F109806\" class=\"graphic graphic_table graphicRef109806 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/20-23\" class=\"abstract_t\">20-23</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>N0 &ndash; no lymph node involvement</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>N1 &ndash; malignant involvement of ipsilateral hilar, peribronchial, and intrapulmonary lymph nodes (<a href=\"image.htm?imageKey=PULM%2F77415\" class=\"graphic graphic_diagnosticimage graphicRef77415 \">image 18</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>N2 &ndash; malignant involvement of ipsilateral mediastinal <span class=\"nowrap\">and/or</span> subcarinal lymph nodes (<a href=\"image.htm?imageKey=PULM%2F50988\" class=\"graphic graphic_diagnosticimage graphicRef50988 \">image 19</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>N3 &ndash; malignant involvement of contralateral mediastinal, contralateral hilar, ipsilateral or contralateral supraclavicular, or ipsilateral or contralateral scalene lymph nodes (<a href=\"image.htm?imageKey=PULM%2F51659\" class=\"graphic graphic_diagnosticimage graphicRef51659 \">image 20</a> and <a href=\"image.htm?imageKey=PULM%2F65827\" class=\"graphic graphic_diagnosticimage graphicRef65827 \">image 21</a> and <a href=\"image.htm?imageKey=PULM%2F50958\" class=\"graphic graphic_diagnosticimage graphicRef50958 \">image 22</a> and <a href=\"image.htm?imageKey=PULM%2F73208\" class=\"graphic graphic_diagnosticimage graphicRef73208 \">image 23</a> and <a href=\"image.htm?imageKey=PULM%2F59386\" class=\"graphic graphic_diagnosticimage graphicRef59386 \">image 24</a> and <a href=\"image.htm?imageKey=PULM%2F111654\" class=\"graphic graphic_diagnosticimage graphicRef111654 \">image 25</a>) </p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Metastases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CT is useful for radiographic staging of suspected metastatic disease. Although CT may identify suspicious lesions, CT alone is considered insufficient to exclude intra- or extra-thoracic metastases such that with the exception of brain, tissue confirmation is still indicated. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H108294217\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Radiographic staging'</a>.) </p><p>Descriptors in this section are per the eighth edition (<a href=\"image.htm?imageKey=ONC%2F109805\" class=\"graphic graphic_table graphicRef109805 \">table 1</a> and <a href=\"image.htm?imageKey=ONC%2F109806\" class=\"graphic graphic_table graphicRef109806 \">table 2</a>) and may be differently staged per the seventh edition (<a href=\"image.htm?imageKey=ONC%2F80099\" class=\"graphic graphic_table graphicRef80099 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/21,22,24,25\" class=\"abstract_t\">21,22,24,25</a>], which, in the United States remains in effect until January 1, 2018; however, outside of the US, the UICC has implemented the eighth edition changes as of January 1, 2017. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CT of the chest may identify pleural nodules, a pleural effusion, a pericardial effusion, or separate parenchymal tumor nodule(s) in the contralateral lung. These abnormalities define M1a disease if they are due to metastatic NSCLC. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CT of bone, brain, or abdomen may detect focal lesions in bone (sclerotic or lytic), brain, liver, adrenal glands, or other abdominal viscera (<a href=\"image.htm?imageKey=PULM%2F111664\" class=\"graphic graphic_diagnosticimage graphicRef111664 \">image 26</a>). These abnormalities define M1b disease (if isolated) or M1c disease (if multiple if they are due to metastatic NSCLC (<a href=\"image.htm?imageKey=PULM%2F51255\" class=\"graphic graphic_diagnosticimage graphicRef51255 \">image 27</a> and <a href=\"image.htm?imageKey=PULM%2F52467\" class=\"graphic graphic_diagnosticimage graphicRef52467 \">image 28</a>). </p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Positron emission tomography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PET is unique in that it provides metabolic rather than anatomic information. In other words, it distinguishes structures on the basis of metabolic activity. PET is typically done from the skull base to the mid-thigh or as a whole body examination, although it should not be used to assess for brain metastases. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H375260\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Whole body PET'</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Technique</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PET begins with the intravenous injection of a radionuclide (18F) bound to an analog of D-glucose (Fluorodeoxyglucose; FDG). While all cells will take up some of the FDG for glycolysis, cells with increased metabolic activity (eg, NSCLC) and cancer cells with aerobic glycolysis, will accumulate more FDG due to upregulation of glycolysis (ie, the Warburg effect). When the patient is imaged, two coincident 0.511Mev photons emitted by the FDG are detected. (See <a href=\"topic.htm?path=thoracic-positron-emission-tomography#H2\" class=\"medical medical_review\">&quot;Thoracic positron emission tomography&quot;, section on 'Technical issues'</a>.)</p><p>Axial, coronal, and sagittal projections of the image can be acquired. Cells with increased metabolic activity appear brighter than the surrounding tissues because they take up more FDG. Ultimately, the FDG is extruded from the cell, filtered by the renal glomeruli, and excreted in the urine.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Tumor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PET can distinguish malignant lesions (hypermetabolic; increased uptake) from benign lesions (normal or decreased uptake) more accurately than CT (<a href=\"image.htm?imageKey=PULM%2F65082\" class=\"graphic graphic_diagnosticimage graphicRef65082 \">image 29</a>) [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/26\" class=\"abstract_t\">26</a>]. However, unlike CT, PET does not have sufficient spatial resolution to determine the local extent of a tumor (ie, T stage from the TNM classification). (See <a href=\"topic.htm?path=computed-tomographic-and-positron-emission-tomographic-scanning-of-pulmonary-nodules#H11\" class=\"medical medical_review\">&quot;Computed tomographic and positron emission tomographic scanning of pulmonary nodules&quot;, section on 'Positron emission tomography (PET)'</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Lymph nodes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PET can detect malignant disease in lymph nodes of normal size (<a href=\"image.htm?imageKey=PULM%2F61004\" class=\"graphic graphic_diagnosticimage graphicRef61004 \">image 30</a>) which explains why PET is consistently more sensitive than CT at detecting occult lymph node metastases [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/26-32\" class=\"abstract_t\">26-32</a>]. </p><p>However, false positive results are relatively common with PET, often due to hypermetabolic inflammatory lesions, which could lead to the assignment of an incorrectly high stage of disease and a missed opportunity for surgical cure. Thus, a positive PET should NOT be considered proof of lymph node metastasis. Tissue sampling is required to confirm the presence of regional lymph node involvement. The value of PET and patient selection for PET scanning in patients with known or suspected NSCLC are discussed separately. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H761452\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Tissue biopsy'</a> and <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H108294217\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Radiographic staging'</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Metastases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Whole body PET detects metastatic NSCLC with greater sensitivity than CT [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/11,33,34\" class=\"abstract_t\">11,33,34</a>], with two exceptions:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PET is not suitable for the detection of brain metastases because of the high glucose uptake of normal surrounding brain tissue. Patients who undergo whole body PET require dedicated brain imaging, preferably with gadolinium-enhanced MRI. (See <a href=\"#H20\" class=\"local\">'Magnetic resonance imaging'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is unclear whether PET is superior to CT for detection of liver metastases. Some series suggest that PET may be superior to CT in patients with NSCLC metastases to the liver [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/35,36\" class=\"abstract_t\">35,36</a>], but not in patients with other types of malignancy [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/37,38\" class=\"abstract_t\">37,38</a>].</p><p/><p>Identification of presumed distant metastatic disease on the basis of PET should be considered tentative. With the exception of brain, tissue sampling is required to confirm that such lesions are due to malignant disease. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H108294217\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Radiographic staging'</a> and <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H761452\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Tissue biopsy'</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Integrated PET/CT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Integrated <span class=\"nowrap\">PET/CT</span> is a modality that combines PET and CT, thus providing overlapping anatomic and metabolic information (<a href=\"image.htm?imageKey=PULM%2F111659\" class=\"graphic graphic_diagnosticimage graphicRef111659 \">image 31</a> and <a href=\"image.htm?imageKey=PULM%2F111658\" class=\"graphic graphic_diagnosticimage graphicRef111658 \">image 32</a>). The technical aspects of integrated <span class=\"nowrap\">PET/CT</span> are the same as those of CT and PET, as described. (See <a href=\"#H5\" class=\"local\">'Computed tomography'</a> above and <a href=\"#H10\" class=\"local\">'Positron emission tomography'</a> above.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Tumor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Integrated <span class=\"nowrap\">PET/CT</span> combines all the advantages of PET and CT. Thus, <span class=\"nowrap\">PET/CT</span> provides the anatomic detail that is necessary to designate the local extent of the primary tumor (ie, T stage). It also distinguishes malignant lesions (increased uptake) from benign lesions (normal or decreased uptake) more accurately than either CT or PET alone [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/39,40\" class=\"abstract_t\">39,40</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Lymph nodes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Integrated <span class=\"nowrap\">PET/CT</span> detects more occult metastases than CT alone [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/11,41-45\" class=\"abstract_t\">11,41-45</a>]. However, false positive results are common with integrated <span class=\"nowrap\">PET/CT,</span> which could lead to the assignment of an incorrectly high stage of disease and a missed opportunity for surgical cure. As a result, a positive integrated <span class=\"nowrap\">PET/CT</span> does not obviate the need for regional lymph node biopsy. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H761452\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Tissue biopsy'</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h3\">Metastases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Integrated <span class=\"nowrap\">PET/CT</span> generally detects more extrathoracic metastases than PET or CT alone [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/46\" class=\"abstract_t\">46</a>]. However, caution is warranted when a solitary extrapulmonary lesion is identified by integrated <span class=\"nowrap\">PET/CT</span> because false positive results are common [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/47\" class=\"abstract_t\">47</a>]. </p><p>Thus, integrated <span class=\"nowrap\">PET/CT</span> that is positive for a possible metastatic lesion should NOT be considered proof of metastasis. Tissue sampling (with the exception of brain) is required to confirm the presence or absence of metastatic disease. (See <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H761452\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Tissue biopsy'</a> and <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H108294217\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'Radiographic staging'</a>.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Magnetic resonance imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MRI is most helpful when brain metastasis, adrenal metastasis, mediastinal invasion (eg, vessel, fat, trachea, and esophagus), chest wall invasion, or spinal cord invasion is suspected on the basis of symptoms or previous imaging (<a href=\"image.htm?imageKey=PULM%2F111663\" class=\"graphic graphic_diagnosticimage graphicRef111663 \">image 33</a> and <a href=\"image.htm?imageKey=PULM%2F111660\" class=\"graphic graphic_diagnosticimage graphicRef111660 \">image 34</a> and <a href=\"image.htm?imageKey=PULM%2F111662\" class=\"graphic graphic_diagnosticimage graphicRef111662 \">image 35</a> and <a href=\"image.htm?imageKey=PULM%2F71057\" class=\"graphic graphic_picture graphicRef71057 \">picture 1</a>). </p><p>When brain metastases must be ruled out, imaging the brain with intravenous gadolinium-based contrast enhanced MRI is the preferred modality, although contrast-enhanced CT is a reasonable alternative if MRI is not available. MRI offers several advantages:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Contrast-enhanced MRI detects brain lesions and differentiates metastases from other central nervous system lesions with greater sensitivity than nonenhanced MRI, contrast-enhanced CT, or nonenhanced CT [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/48,49\" class=\"abstract_t\">48,49</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Contrast-enhanced MRI uses a paramagnetic gadolinium-based contrast agent, rather than an iodinated contrast agent. The paramagnetic agent tends to be better tolerated and can be used in many patients who have contraindications to iodinated contrast material, provided they have normal renal function. However, gadolinium-based contrast agents should be avoided in patients with renal insufficiency due to the risk of inducing nephrogenic systemic fibrosis [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/50\" class=\"abstract_t\">50</a>], though the risk is very low, particularly with <a href=\"topic.htm?path=gadobenate-dimeglumine-drug-information\" class=\"drug drug_general\">Gadobenate Dimeglumine</a> [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/51\" class=\"abstract_t\">51</a>]. (See <a href=\"topic.htm?path=nephrogenic-systemic-fibrosis-nephrogenic-fibrosing-dermopathy-in-advanced-renal-failure#H4\" class=\"medical medical_review\">&quot;Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure&quot;, section on 'Gadolinium'</a>.)</p><p/><p>MRI may also be helpful in distinguishing benign, fat-containing adrenal adenomas from adrenal metastases. Adrenal adenomas have low signal intensity on out-of-phase gradient echo MRI due to their intracellular fat content [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/52,53\" class=\"abstract_t\">52,53</a>]. (See <a href=\"topic.htm?path=the-adrenal-incidentaloma\" class=\"medical medical_review\">&quot;The adrenal incidentaloma&quot;</a>.) </p><p>MRI of lymph nodes for staging purposes has been utilized, but CT is preferred [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/54\" class=\"abstract_t\">54</a>]. </p><p>Integrated <span class=\"nowrap\">PET/MRI</span> units are utilized in specialized centers on an experimental basis [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/55\" class=\"abstract_t\">55</a>].</p><p>The technical aspects of MRI are described separately. (See <a href=\"topic.htm?path=magnetic-resonance-imaging-of-the-thorax\" class=\"medical medical_review\">&quot;Magnetic resonance imaging of the thorax&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Bone scan</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Imaging of the skeleton is indicated in patients with suspected NSCLC who have symptoms (eg, focal bone pain), signs (eg, difficulty weight bearing), or laboratory abnormalities (eg, elevated alkaline phosphatase with normal gammaglutamyl transpeptidase) that raise the suspicion for bone metastases [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/29,56-58\" class=\"abstract_t\">29,56-58</a>]. While in the past, technetium 99m methylene diphosphonate (MDP or medronate) nuclear medicine bone scans were frequently performed for the detection of bone metastases, they have been largely displaced by PET. Although bone scans are less time consuming with better ability to detect osteoblastic lesions, PET has better specificity and can also identify metastases to organs other than bone [<a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/36,59\" class=\"abstract_t\">36,59</a>]. </p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Imaging is a key component of the diagnosis, staging, and restaging of patients with suspected or known non-small cell lung cancer (NSCLC). Imaging identifies target lesions for sampling and also assists in planning therapy. (See <a href=\"#H3706647543\" class=\"local\">'Goals of imaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Imaging modalities are insufficient to definitively diagnose and stage lung cancer such that, with the exception of brain, tissue biopsy of the primary tumor <span class=\"nowrap\">and/or</span> metastases is necessary. (See <a href=\"#H3706647543\" class=\"local\">'Goals of imaging'</a> above and <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;</a> and <a href=\"#H2\" class=\"local\">'TNM staging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Imaging is integral to the staging of NSCLC, which is based upon the tumor node metastasis (TNM) staging system. Imaging coordinates primary tumor size (T), extent of regional lymph node involvement (N), and presence or absence of distant metastasis (M) (<a href=\"image.htm?imageKey=ONC%2F109805\" class=\"graphic graphic_table graphicRef109805 \">table 1</a> and <a href=\"image.htm?imageKey=ONC%2F109806\" class=\"graphic graphic_table graphicRef109806 \">table 2</a>). (See <a href=\"#H2\" class=\"local\">'TNM staging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest radiography is frequently the initial test performed to evaluate symptoms suggestive of lung cancer that prompt computed tomography (CT) of the chest. (See <a href=\"#H4\" class=\"local\">'Chest radiography'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CT of the chest extending through the adrenal glands should be performed in all patients with suspected NSCLC to characterize the local extent of the primary tumor (size, invasion to adjacent structures, associated atelectasis, additional nodules; ie, T1-4 stage of the TNM system) and any potential lymph node metastases (N1,N2,N3) (<a href=\"image.htm?imageKey=ONC%2F109805\" class=\"graphic graphic_table graphicRef109805 \">table 1</a> and <a href=\"image.htm?imageKey=ONC%2F109806\" class=\"graphic graphic_table graphicRef109806 \">table 2</a>). (See <a href=\"#H5\" class=\"local\">'Computed tomography'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CT of extrathoracic organs, when performed, may also identify potential distant metastases (M1a, M1b, M1c). The identification and characterization of disease extent by CT facilitates the selection of modality and site for biopsy to diagnose <span class=\"nowrap\">and/or</span> stage patients with NSCLC. (See <a href=\"#H5\" class=\"local\">'Computed tomography'</a> above and <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer#H108294779\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;, section on 'CT scan of the chest'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Whole body positron emission tomography (PET), when positive, may provide additional evidence that the primary tumor is malignant and in addition, may identify occult lymph node, or distant metastases. However, unlike CT, PET does not have sufficient spatial resolution to determine the local extent of a tumor (ie, T stage). Integrated <span class=\"nowrap\">PET/CT</span> combines the advantages of both modalities and is preferred by many experts. (See <a href=\"#H10\" class=\"local\">'Positron emission tomography'</a> above and <a href=\"#H15\" class=\"local\">'Integrated PET/CT'</a> above and <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MRI is most helpful when brain metastasis, adrenal metastasis, mediastinal invasion (vessel, fat, trachea, esophagus), chest wall invasion, or spinal cord invasion is suspected on the basis of CT findings or symptoms. (See <a href=\"#H20\" class=\"local\">'Magnetic resonance imaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>While in the past, technetium 99m methylene diphosphonate (MDP or medronate) nuclear medicine bone scans were frequently performed for the detection of bone metastases, they have been largely displaced by PET. (See <a href=\"#H21\" class=\"local\">'Bone scan'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/1\" class=\"nounderline abstract_t\">Carter BW, Glisson BS, Truong MT, Erasmus JJ. Small cell lung carcinoma: staging, imaging, and treatment considerations. Radiographics 2014; 34:1707.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/2\" class=\"nounderline abstract_t\">Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e211S.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/3\" class=\"nounderline abstract_t\">Nickoloff EL, Lu ZF, Dutta AK, So JC. Radiation dose descriptors: BERT, COD, DAP, and other strange creatures. Radiographics 2008; 28:1439.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/4\" class=\"nounderline abstract_t\">Wall BF, Hart D. Revised radiation doses for typical X-ray examinations. Report on a recent review of doses to patients from medical X-ray examinations in the UK by NRPB. National Radiological Protection Board. Br J Radiol 1997; 70:437.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/5\" class=\"nounderline abstract_t\">Parry RA, Glaze SA, Archer BR. The AAPM/RSNA physics tutorial for residents. Typical patient radiation doses in diagnostic radiology. Radiographics 1999; 19:1289.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/6\" class=\"nounderline abstract_t\">Chou SH, Kicska GA, Pipavath SN, Reddy GP. Digital tomosynthesis of the chest: current and emerging applications. Radiographics 2014; 34:359.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/7\" class=\"nounderline abstract_t\">Patz EF Jr, Erasmus JJ, McAdams HP, et al. Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. Radiology 1999; 212:56.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/8\" class=\"nounderline abstract_t\">Hendee WR, O'Connor MK. Radiation risks of medical imaging: separating fact from fantasy. Radiology 2012; 264:312.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/9\" class=\"nounderline abstract_t\">Amis ES Jr, Butler PF, Applegate KE, et al. American College of Radiology white paper on radiation dose in medicine. J Am Coll Radiol 2007; 4:272.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/10\" class=\"nounderline abstract_t\">Mayo JR, Aldrich J, Muller NL, Fleischner Society. Radiation exposure at chest CT: a statement of the Fleischner Society. Radiology 2003; 228:15.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/11\" class=\"nounderline abstract_t\">G&aacute;mez C, Rosell R, Fern&aacute;ndez A, et al. PET/CT fusion scan in lung cancer: current recommendations and innovations. J Thorac Oncol 2006; 1:74.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/12\" class=\"nounderline abstract_t\">Iezzi A, Magarelli N, Carriero A, et al. [Staging of pulmonary apex tumors. Computerized tomography versus magnetic resonance]. Radiol Med 1994; 88:24.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/13\" class=\"nounderline abstract_t\">Mayo JR. Magnetic resonance imaging of the chest. Where we stand. Radiol Clin North Am 1994; 32:795.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/14\" class=\"nounderline abstract_t\">Laissy JP, Soyer P, Sekkal SR, et al. Assessment of vascular involvement with magnetic resonance angiography (MRA) in Pancoast syndrome. Magn Reson Imaging 1995; 13:523.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/15\" class=\"nounderline abstract_t\">Schr&ouml;der C, Sch&ouml;nhofer B, Vogel B. Transesophageal echographic determination of aortic invasion by lung cancer. Chest 2005; 127:438.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/16\" class=\"nounderline abstract_t\">Obeid AI. Transesophageal echocardiography and staging in lung cancer: a view from the rear window. Chest 2005; 127:420.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/17\" class=\"nounderline abstract_t\">El-Sherief AH, Lau CT, Wu CC, et al. International association for the study of lung cancer (IASLC) lymph node map: radiologic review with CT illustration. Radiographics 2014; 34:1680.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/18\" class=\"nounderline abstract_t\">Walker CM, Chung JH, Abbott GF, et al. Mediastinal lymph node staging: from noninvasive to surgical. AJR Am J Roentgenol 2012; 199:W54.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/19\" class=\"nounderline abstract_t\">Restrepo CS, Eraso A, Ocazionez D, et al. The diaphragmatic crura and retrocrural space: normal imaging appearance, variants, and pathologic conditions. Radiographics 2008; 28:1289.</a></li><li class=\"breakAll\">UICC TNM Classification of Malignant Tumors, 6th Ed, Sobin L, Wittekind C (Eds), Wiley-Liss, New York 2002. p.272.</li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/21\" class=\"nounderline abstract_t\">Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:39.</a></li><li class=\"breakAll\">AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 8th edition, Amin MB, Edge SB, Greene FL et al (Eds), Springer, Chicago 2017.</li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/23\" class=\"nounderline abstract_t\">Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:651.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/24\" class=\"nounderline abstract_t\">Detterbeck FC, Chansky K, Groome P, et al. The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol 2016; 11:1433.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/25\" class=\"nounderline abstract_t\">Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. Chest 2017; 151:193.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/26\" class=\"nounderline abstract_t\">Vansteenkiste JF, Stroobants SS. PET scan in lung cancer: current recommendations and innovation. J Thorac Oncol 2006; 1:71.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/27\" class=\"nounderline abstract_t\">Patz EF Jr, Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995; 108:1617.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/28\" class=\"nounderline abstract_t\">Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343:254.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/29\" class=\"nounderline abstract_t\">van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359:1388.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/30\" class=\"nounderline abstract_t\">Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003; 139:879.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/31\" class=\"nounderline abstract_t\">Fischer BM, Mortensen J, H&oslash;jgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2001; 2:659.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/32\" class=\"nounderline abstract_t\">Birim O, Kappetein AP, Stijnen T, Bogers AJ. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 2005; 79:375.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/33\" class=\"nounderline abstract_t\">Bury T, Dowlati A, Paulus P, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997; 10:2529.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/34\" class=\"nounderline abstract_t\">Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998; 66:886.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/35\" class=\"nounderline abstract_t\">Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995; 60:1573.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/36\" class=\"nounderline abstract_t\">Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212:803.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/37\" class=\"nounderline abstract_t\">Hustinx R, Paulus P, Jacquet N, et al. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol 1998; 9:397.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/38\" class=\"nounderline abstract_t\">Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133:510.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/39\" class=\"nounderline abstract_t\">Yi CA, Lee KS, Kim BT, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 2006; 47:443.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/40\" class=\"nounderline abstract_t\">Kim SK, Allen-Auerbach M, Goldin J, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 2007; 48:214.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/41\" class=\"nounderline abstract_t\">Pozo-Rodr&iacute;guez F, Mart&iacute;n de Nicol&aacute;s JL, S&aacute;nchez-Nistal MA, et al. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol 2005; 23:8348.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/42\" class=\"nounderline abstract_t\">Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003; 229:526.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/43\" class=\"nounderline abstract_t\">Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348:2500.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/44\" class=\"nounderline abstract_t\">Cerfolio RJ, Ojha B, Bryant AS, et al. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004; 78:1017.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/45\" class=\"nounderline abstract_t\">Wu Y, Li P, Zhang H, et al. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Int J Cancer 2013; 132:E37.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/46\" class=\"nounderline abstract_t\">De Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J 2007; 29:995.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/47\" class=\"nounderline abstract_t\">Lardinois D, Weder W, Roudas M, et al. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol 2005; 23:6846.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/48\" class=\"nounderline abstract_t\">Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:178S.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/49\" class=\"nounderline abstract_t\">Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999; 44:275.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/50\" class=\"nounderline abstract_t\">Weinreb JC. Which study when? Is gadolinium-enhanced MR imaging safer than iodine-enhanced CT? Radiology 2008; 249:3.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/51\" class=\"nounderline abstract_t\">Nandwana SB, Moreno CC, Osipow MT, et al. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function? Radiology 2015; 276:741.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/52\" class=\"nounderline abstract_t\">Reinig JW, Stutley JE, Leonhardt CM, et al. Differentiation of adrenal masses with MR imaging: comparison of techniques. Radiology 1994; 192:41.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/53\" class=\"nounderline abstract_t\">Reinig JW, Doppman JL, Dwyer AJ, et al. Adrenal masses differentiated by MR. Radiology 1986; 158:81.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/54\" class=\"nounderline abstract_t\">Peerlings J, Troost EG, Nelemans PJ, et al. The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. Radiology 2016; 281:86.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/55\" class=\"nounderline abstract_t\">Yi CA, Lee KS, Lee HY, et al. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial. Cancer 2013; 119:1784.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/56\" class=\"nounderline abstract_t\">Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med 1997; 156:320.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/57\" class=\"nounderline abstract_t\">Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/58\" class=\"nounderline abstract_t\">Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123:1693.</a></li><li><a href=\"https://www.uptodate.com/contents/imaging-of-lung-cancer/abstract/59\" class=\"nounderline abstract_t\">Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25:1244.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4599 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H23\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H3706647543\" id=\"outline-link-H3706647543\">GOALS OF IMAGING</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">TNM STAGING</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">IMAGING MODALITIES</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Chest radiography</a><ul><li><a href=\"#H3511855298\" id=\"outline-link-H3511855298\">- Radiation dose</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">Computed tomography</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">- Technique</a></li><li><a href=\"#H2853752449\" id=\"outline-link-H2853752449\">- Radiation dose</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Tumor</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Lymph nodes</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Metastases</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">Positron emission tomography</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">- Technique</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- Tumor</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">- Lymph nodes</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Metastases</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">Integrated PET/CT</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">- Tumor</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">- Lymph nodes</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">- Metastases</a></li></ul></li><li><a href=\"#H20\" id=\"outline-link-H20\">Magnetic resonance imaging</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Bone scan</a></li></ul></li><li><a href=\"#H23\" id=\"outline-link-H23\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/4599|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/111651\" class=\"graphic graphic_diagnosticimage\">- Radiograph RUL SPN</a></li><li><a href=\"image.htm?imageKey=PULM/111656\" class=\"graphic graphic_diagnosticimage\">- Lung cancer and ILD</a></li><li><a href=\"image.htm?imageKey=PULM/111657\" class=\"graphic graphic_diagnosticimage\">- Advanced lung cancer</a></li><li><a href=\"image.htm?imageKey=PULM/111652\" class=\"graphic graphic_diagnosticimage\">- Cavitating lung cancer</a></li><li><a href=\"image.htm?imageKey=PULM/111653\" class=\"graphic graphic_diagnosticimage\">- Lung cancer local invasion</a></li><li><a href=\"image.htm?imageKey=PULM/112827\" class=\"graphic graphic_diagnosticimage\">- CT spiculated nodule</a></li><li><a href=\"image.htm?imageKey=PULM/57134\" class=\"graphic graphic_diagnosticimage\">- Lepidic adenocarcinoma CT</a></li><li><a href=\"image.htm?imageKey=PULM/56988\" class=\"graphic graphic_diagnosticimage\">- Mainstem bronchus mass CT</a></li><li><a href=\"image.htm?imageKey=PULM/111661\" class=\"graphic graphic_diagnosticimage\">- CT endobronchial cancer</a></li><li><a href=\"image.htm?imageKey=PULM/59036\" class=\"graphic graphic_diagnosticimage\">- Bronchogenic carcinoma CT</a></li><li><a href=\"image.htm?imageKey=PULM/73744\" class=\"graphic graphic_diagnosticimage\">- Bronchogenic carcinoma CT I</a></li><li><a href=\"image.htm?imageKey=PULM/53784\" class=\"graphic graphic_diagnosticimage\">- Bronchogenic carcinoma CT II</a></li><li><a href=\"image.htm?imageKey=PULM/71610\" class=\"graphic graphic_diagnosticimage\">- Phrenic nerve invasion</a></li><li><a href=\"image.htm?imageKey=PULM/111655\" class=\"graphic graphic_diagnosticimage\">- Lung cancer involving phrenic nerve</a></li><li><a href=\"image.htm?imageKey=PULM/58664\" class=\"graphic graphic_diagnosticimage\">- Pulmonary vein invasion</a></li><li><a href=\"image.htm?imageKey=PULM/64447\" class=\"graphic graphic_diagnosticimage\">- Bronchogenic carcinoma CT III</a></li><li><a href=\"image.htm?imageKey=PULM/105319\" class=\"graphic graphic_diagnosticimage\">- Superior sulcus tumor</a></li><li><a href=\"image.htm?imageKey=PULM/77415\" class=\"graphic graphic_diagnosticimage\">- Hilar lymph nodes CT I</a></li><li><a href=\"image.htm?imageKey=PULM/50988\" class=\"graphic graphic_diagnosticimage\">- Paratracheal lymph node CT</a></li><li><a href=\"image.htm?imageKey=PULM/51659\" class=\"graphic graphic_diagnosticimage\">- Lymph node enlargement CT</a></li><li><a href=\"image.htm?imageKey=PULM/65827\" class=\"graphic graphic_diagnosticimage\">- Paratracheal and subcarinal lymph node CT I</a></li><li><a href=\"image.htm?imageKey=PULM/50958\" class=\"graphic graphic_diagnosticimage\">- Prevascular adenopathy CT</a></li><li><a href=\"image.htm?imageKey=PULM/73208\" class=\"graphic graphic_diagnosticimage\">- Bronchogenic carcinoma CT IV</a></li><li><a href=\"image.htm?imageKey=PULM/59386\" class=\"graphic graphic_diagnosticimage\">- Tracheobronchial lymph nodes CT</a></li><li><a href=\"image.htm?imageKey=PULM/111654\" class=\"graphic graphic_diagnosticimage\">- Lung cancer lymphangitis</a></li><li><a href=\"image.htm?imageKey=PULM/111664\" class=\"graphic graphic_diagnosticimage\">- CT adrenal metastases II</a></li><li><a href=\"image.htm?imageKey=PULM/51255\" class=\"graphic graphic_diagnosticimage\">- Lung cancer liver metastases CT </a></li><li><a href=\"image.htm?imageKey=PULM/52467\" class=\"graphic graphic_diagnosticimage\">- Left adrenal metastasis CT</a></li><li><a href=\"image.htm?imageKey=PULM/65082\" class=\"graphic graphic_diagnosticimage\">- FDG scan II</a></li><li><a href=\"image.htm?imageKey=PULM/61004\" class=\"graphic graphic_diagnosticimage\">- Right lung tumor PET scan</a></li><li><a href=\"image.htm?imageKey=PULM/111659\" class=\"graphic graphic_diagnosticimage\">- CT and PET lung cancer</a></li><li><a href=\"image.htm?imageKey=PULM/111658\" class=\"graphic graphic_diagnosticimage\">- PET lung cancer</a></li><li><a href=\"image.htm?imageKey=PULM/111663\" class=\"graphic graphic_diagnosticimage\">- MRI lung cancer with liver infiltration</a></li><li><a href=\"image.htm?imageKey=PULM/111660\" class=\"graphic graphic_diagnosticimage\">- MRI Pancoast's</a></li><li><a href=\"image.htm?imageKey=PULM/111662\" class=\"graphic graphic_diagnosticimage\">- MRI brain metastasis</a></li></ul></li><li><div id=\"PULM/4599|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/73945\" class=\"graphic graphic_figure\">- IASLC lymph node map</a></li></ul></li><li><div id=\"PULM/4599|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/71057\" class=\"graphic graphic_picture\">- Squamous cell carcinoma MRI</a></li></ul></li><li><div id=\"PULM/4599|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/109805\" class=\"graphic graphic_table\">- TNM descriptors 8th edition TNM lung classification</a></li><li><a href=\"image.htm?imageKey=ONC/109806\" class=\"graphic graphic_table\">- 7th edition descriptors, T and M categories and 8th edition</a></li><li><a href=\"image.htm?imageKey=ONC/80099\" class=\"graphic graphic_table\">- Lung cancer TNM staging 7th edition</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=breast-imaging-for-cancer-screening-mammography-and-ultrasonography\" class=\"medical medical_review\">Breast imaging for cancer screening: Mammography and ultrasonography</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=computed-tomographic-and-positron-emission-tomographic-scanning-of-pulmonary-nodules\" class=\"medical medical_review\">Computed tomographic and positron emission tomographic scanning of pulmonary nodules</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-evaluation-of-the-incidental-pulmonary-nodule\" class=\"medical medical_review\">Diagnostic evaluation of the incidental pulmonary nodule</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-preoperative-pulmonary-risk\" class=\"medical medical_review\">Evaluation of preoperative pulmonary risk</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=magnetic-resonance-imaging-of-the-thorax\" class=\"medical medical_review\">Magnetic resonance imaging of the thorax</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nephrogenic-systemic-fibrosis-nephrogenic-fibrosing-dermopathy-in-advanced-renal-failure\" class=\"medical medical_review\">Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer\" class=\"medical medical_review\">Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=procedures-for-tissue-biopsy-in-patients-with-suspected-non-small-cell-lung-cancer\" class=\"medical medical_review\">Procedures for tissue biopsy in patients with suspected non-small cell lung cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selection-of-modality-for-diagnosis-and-staging-of-patients-with-suspected-non-small-cell-lung-cancer\" class=\"medical medical_review\">Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-adrenal-incidentaloma\" class=\"medical medical_review\">The adrenal incidentaloma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=thoracic-positron-emission-tomography\" class=\"medical medical_review\">Thoracic positron emission tomography</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=transesophageal-echocardiography-indications-complications-and-normal-views\" class=\"medical medical_review\">Transesophageal echocardiography: Indications, complications, and normal views</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tumor-node-metastasis-tnm-staging-system-for-lung-cancer\" class=\"medical medical_review\">Tumor, Node, Metastasis (TNM) staging system for lung cancer</a></li></ul></div></div>","javascript":null}